Abstract
Enormous strides have been made in sequencing technology, multi-gene panels, evidence-based guidelines, and actionable results. We have been moving from reactive pharmacogenomic testing based on single gene analysis to broad pre-emptive testing, where the pharmacogenetic information is available in electronic health records and prescription systems enabling dosing decisions before a prescription is written.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have